These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 29440887

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
    D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF, AUGMENT COPD study investigators.
    Respir Res; 2014 Oct 14; 15(1):123. PubMed ID: 25756831
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
    Miravitlles M, Chapman KR, Chuecos F, Ribera A, Gil EG.
    Int J Chron Obstruct Pulmon Dis; 2016 Oct 14; 11():2041-53. PubMed ID: 27621610
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D, D'Urzo AD, Chuecos F, Muñoz A, Garcia Gil E.
    Respir Res; 2017 May 30; 18(1):106. PubMed ID: 28558833
    [Abstract] [Full Text] [Related]

  • 8. Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year.
    Donohue JF, Ganapathy V, Bollu V, Stensland MD, Nelson LM.
    Clin Ther; 2017 Jan 30; 39(1):66-74. PubMed ID: 28011247
    [Abstract] [Full Text] [Related]

  • 9. Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol.
    Ganapathy V, Stensland MD.
    Int J Chron Obstruct Pulmon Dis; 2017 Jan 30; 12():1793-1801. PubMed ID: 28694692
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Fluticasone propionate/formoterol for COPD management: a randomized controlled trial.
    Papi A, Dokic D, Tzimas W, Mészáros I, Olech-Cudzik A, Koroknai Z, McAulay K, Mersmann S, Dalvi PS, Overend T.
    Int J Chron Obstruct Pulmon Dis; 2017 Jan 30; 12():1961-1971. PubMed ID: 28740376
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
    Sethi S, Kerwin E, Watz H, Ferguson GT, Mroz RM, Segarra R, Molins E, Jarreta D, Garcia Gil E.
    Int J Chron Obstruct Pulmon Dis; 2019 Jan 30; 14():667-682. PubMed ID: 30962681
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of baseline symptom burden on treatment response in COPD.
    Martinez FJ, Abrahams RA, Ferguson GT, Bjermer L, Grönke L, Voß F, Singh D.
    Int J Chron Obstruct Pulmon Dis; 2019 Jan 30; 14():181-194. PubMed ID: 30655665
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.
    Celli BR, Navaie M, Xu Z, Cho-Reyes S, Dembek C, Gilmer TP.
    Int J Chron Obstruct Pulmon Dis; 2019 Jan 30; 14():1019-1031. PubMed ID: 31190787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.